Redefining therapeutics in vATTR: Evaluation of response predictors to tafamidis and patisiran treatment in a non-endemic area. A proposal for a novel individualised therapeutic approach
Laura Martínez‐Vicente, V. Gajate-García, Gerardo Gutiérrez‐Gutiérrez, Ángel Luis Guerrero Peral et autres
Hereditary transthyretin amyloidosis (vATTR) is a progressive genetic disorder with several approved treatments. We investigated treatment responses to tafamidis and patisiran in vATTR patients to identify predictive response factors. Retrospective analysis on vATTR patients treated with tafamidis or patisiran from October 2012 …
es (code pays fourni par la source)
0 citations
Neurología